Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
about
Imiquimod for anogenital warts in non-immunocompromised adultsTraditional Chinese medicinal herbs for condyloma acuminatumAdvances in the use of topical imiquimod to treat dermatologic disordersImiquimod for the treatment of genital warts: a quantitative systematic reviewHPV Carcinomas in Immunocompromised PatientsSuccessful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulatorFemale genital warts: global trends and treatmentsEfficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulationToll-like receptors control autophagy.Recent advances: Dermatology.Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream.Successful treatment of butcher's warts with imiquimod 5% cream.Extensive condyloma acuminata treated with imiquimod 5% cream: a case report.What's new in the treatment of viral warts in children.External genital warts: diagnosis, treatment, and prevention.Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment.Therapy of cutaneous human Papillomavirus infections.Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier.Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.Topical treatment of intraepithelial penile carcinoma with imiquimod.Nursing care and treatment of the patient with human papillomavirus.HPV-related vulvar intraepithelial neoplasia: outcome of different management modalities.Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.Warts (genital)Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options.Recent advances: Sexually transmitted infections.Induction of vitiligo after imiquimod treatment of condylomata acuminataAdvances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis.Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).Recent advances in diagnosis and therapy of human papillomaviruses.Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled studyHuman papillomavirus infections: epidemiology, pathogenesis, and therapy.Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.2012 European guideline for the management of anogenital warts.Human papillomavirus: clinical significance and malignant potential.An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.Imiquimod in the treatment of cutaneous warts: an evidence-based review.Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
P2860
Q24188125-1C8B2471-1DEE-4A33-8620-A387B8721A6EQ24197808-BA1BF810-C3DB-435A-9458-E85FF27A8A06Q24647413-6D31CD76-B01F-496E-BA2F-D7C3FE79BB03Q24799636-1EC09C21-8B57-4DEF-A8BF-0BC1BB044961Q26799629-22649218-CF17-408B-AA9B-48FF4C8F5F58Q28203663-663F841E-E59F-4792-8009-8B2A350142DDQ28346547-0DC595BC-9053-4DD8-940E-86EA122BE80BQ28540777-16390A5B-8CC5-45D6-958B-D0313219440FQ30481722-A08E50F2-E603-40DB-86DC-64DE10E7F59DQ30850471-2726E602-28FE-4D14-A723-3AFAA2E69CA7Q31025216-22DF9F20-9B1D-4D89-8931-8F51195C67CBQ31025230-46C9F9F8-E24A-4017-A48A-E24CF0B51470Q31025243-85B029A8-5F1C-45DA-A5B8-7C9196B5F9C3Q31068156-EC9D15C9-2A47-4A7C-A047-5AF81663EBD4Q31112715-F4ACCFFE-0C3B-4469-A553-4AE4D2F2B874Q31125993-05291303-4B9D-4685-B5FA-31BE08312A2DQ31133083-E9A6952C-6961-4957-8993-C013A1C4BEB4Q31901669-2FEA074B-F06E-44D9-9F09-BACC33C8CF55Q31934243-7E4DB5E7-2FBB-489C-8161-4FEC5D33223EQ33195010-4A1C2F90-785E-49CC-B3E3-B586456E1793Q33266511-9E1D49A2-5D92-4296-AE0B-51B571AC89B6Q33282945-F7DC046D-5216-43B9-8F38-ADEB6DA21945Q33445369-00068781-0BF8-4FA0-B4C0-4251359E7AD3Q33448263-62D3F4FF-51B9-48E1-98C7-9B5E2E074CCFQ33512007-9FFC3381-1CEA-439E-87E5-78AB82A69454Q33805422-1819DAFB-7E7A-4022-B21D-E52CAACDCE8BQ33855460-4D1A74D0-2AB3-4BBD-AA22-B895F44787B4Q33955466-A9F56B61-7457-44AF-A30B-776389911B24Q33981870-52E6730D-4566-49E3-B45A-4881891E389DQ33981920-02063CEB-6018-4416-9A93-03AAA3404B3CQ33983310-81F73C39-7DF5-4C77-B629-45EB3B408184Q34074998-77E59E31-866F-4ABC-90DE-A68C4385349EQ34144914-897FEFA1-51C2-4F6B-B8A6-65395D3C6E13Q34204141-5AE55F0F-C4F1-4DB3-82AF-1DFF766A5A72Q34230429-D06E88DE-2A70-4040-9D5A-8F0A0BF74E16Q34260588-05DF8F8E-0C57-4DDD-96B6-42C2D84957E3Q34394146-EE3589A6-1338-47CA-8531-307D38DBA31EQ34431983-B3AADC95-429F-4F22-951D-A41DB11DA071Q34436779-949F99BB-C963-466F-B8C8-BCB9E7803A7EQ34459603-D985A4CF-7C61-4442-BCC3-37A31D98A876
P2860
Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@en
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@nl
type
label
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@en
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@nl
prefLabel
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@en
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@nl
P2093
P1433
P1476
Self-administered topical 5% i ...... y Group. Human PapillomaVirus.
@en
P2093
A Ferenczy
A J Hougham
K A Schmitt
P356
10.1001/ARCHDERM.134.1.25
P577
1998-01-01T00:00:00Z